Top ▲

platelet derived growth factor receptor beta

Click here for help

Target not currently curated in GtoImmuPdb

Target id: 1804

Nomenclature: platelet derived growth factor receptor beta

Abbreviated Name: PDGFRβ

Family: Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family

Contents:

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 1106 5q32 PDGFRB platelet derived growth factor receptor beta
Mouse 1 1098 18 34.41 cM Pdgfrb platelet derived growth factor receptor, beta polypeptide
Rat 1 1097 18q12.1 Pdgfrb platelet derived growth factor receptor beta
Previous and Unofficial Names Click here for help
CD140b | JTK12 | PDGFR1 | PDGFR-beta | platelet-derived growth factor receptor beta polypeptide | platelet-derived growth factor receptor, beta polypeptide | platelet derived growth factor receptor, beta polypeptide | platelet derived growth factor receptor
Database Links Click here for help
Alphafold P09619 (Hs), P05622 (Mm), Q05030 (Rn)
BRENDA 2.7.10.1
CATH/Gene3D 2.60.40.10
ChEMBL Target CHEMBL1913 (Hs), CHEMBL2749 (Mm), CHEMBL4125 (Rn)
DrugBank Target P09619 (Hs)
Ensembl Gene ENSG00000113721 (Hs), ENSMUSG00000024620 (Mm), ENSRNOG00000018461 (Rn)
Entrez Gene 5159 (Hs), 18596 (Mm), 24629 (Rn)
Human Protein Atlas ENSG00000113721 (Hs)
KEGG Enzyme 2.7.10.1
KEGG Gene hsa:5159 (Hs), mmu:18596 (Mm), rno:24629 (Rn)
OMIM 173410 (Hs)
Orphanet ORPHA138376 (Hs)
Pharos P09619 (Hs)
RefSeq Nucleotide NM_002609 (Hs), NM_001146268 (Mm), NM_031525 (Rn)
RefSeq Protein NP_002600 (Hs), NP_032835 (Mm), NP_001139740 (Mm), NP_113713 (Rn)
UniProtKB P09619 (Hs), P05622 (Mm), Q05030 (Rn)
Wikipedia PDGFRB (Hs)
Selected 3D Structures Click here for help
Image of receptor 3D structure from RCSB PDB
Description:  The structure of a platelet derived growth factor receptor complex
PDB Id:  3MJG
Resolution:  2.3Å
Species:  Human
References:  42
Enzyme Reaction Click here for help
EC Number: 2.7.10.1
Endogenous ligands (Human)
PDGF

Download all structure-activity data for this target as a CSV file go icon to follow link

Inhibitors
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
AC710 Small molecule or natural product Click here for species-specific activity table Hs Inhibition 9.0 pKd 26
⤷ pKd 9.0 (Kd 1x10-9 M) [26]
crenolanib Small molecule or natural product Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibition 8.5 pKd 15
⤷ pKd 8.5 (Kd 3.2x10-9 M) [15]
quizartinib Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 8.1 pKd 5
⤷ pKd 8.1 (Kd 7.7x10-9 M) [5]
naporafenib Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 7.8 pKd 39
⤷ pKd 7.8 (Kd 1.4x10-8 M) [39]
Description: Binding affinity determined using the KinomeScan® platform.
compound 5e [PMID: 28580438] Small molecule or natural product Click here for species-specific activity table Immunopharmacology Ligand Hs Inhibition 7.6 pKd 19
⤷ pKd 7.6 (Kd 2.8x10-8 M) [19]
IACS-9439 Small molecule or natural product Click here for species-specific activity table Hs Inhibition 6.3 pKd 7
⤷ pKd 6.3 (Kd 4.5x10-7 M) [7]
salvianolic acid B Small molecule or natural product Click here for species-specific activity table Hs Binding 5.2 pKd 25
⤷ pKd 5.2 (Kd 6.15x10-6 M) [25]
Description: Binding affinity determined by surface plasmon resonance analysis
sunitinib Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 8.1 pKi 30
⤷ pKi 8.1 (Ki 8x10-9 M) [30]
PD166285 Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 7.0 pKi 37
⤷ pKi 7.0 (Ki 9.83x10-8 M) [37]
CP-673451 Small molecule or natural product Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 9.0 pIC50 41
⤷ pIC50 9.0 (IC50 1x10-9 M) [41]
compound 8h [PMID: 22765894] Small molecule or natural product Click here for species-specific activity table Hs Inhibition 8.9 pIC50 22
⤷ pIC50 8.9 (IC50 1.3x10-9 M) [22]
compound 8i [PMID: 22765894] Small molecule or natural product Click here for species-specific activity table Hs Inhibition 8.8 pIC50 52
⤷ pIC50 8.8 (IC50 1.5x10-9 M) [52]
M4205 Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 8.6 pIC50 3
⤷ pIC50 8.6 (IC50 2.6x10-9 M) [3]
Description: Biochemical inhibitory potency
SU11652 Small molecule or natural product Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 8.5 pIC50 44
⤷ pIC50 8.5 (IC50 3x10-9 M) [44]
SU-14813 Small molecule or natural product Primary target of this compound Click here for species-specific activity table Hs Inhibition 8.4 pIC50 38
⤷ pIC50 8.4 (IC50 4x10-9 M) [38]
famitinib Small molecule or natural product Primary target of this compound Click here for species-specific activity table Hs Inhibition 8.4 pIC50 6
⤷ pIC50 8.4 (IC50 4x10-9 M) [6]
PDGF receptor tyrosine kinase inhibitor IV Small molecule or natural product Primary target of this compound Hs Inhibition 8.4 pIC50 17
⤷ pIC50 8.4 (IC50 4.2x10-9 M) [17]
cediranib Small molecule or natural product Primary target of this compound Click here for species-specific activity table Hs Inhibition 8.3 pIC50 48
⤷ pIC50 8.3 (IC50 5x10-9 M) [48]
sunitinib Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 8.2 pIC50 23
⤷ pIC50 8.2 (IC50 5.7x10-9 M) [23]
lucitanib Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 8.1 pIC50 53
⤷ pIC50 8.1 (IC50 8x10-9 M) [53]
henatinib Small molecule or natural product Click here for species-specific activity table Hs Inhibition 8.0 pIC50 6
⤷ pIC50 8.0 (IC50 1.1x10-8 M) [6]
dovitinib Small molecule or natural product Click here for species-specific activity table Hs Inhibition 7.6 – 8.3 pIC50 40,46
⤷ pIC50 7.6 – 8.3 (IC50 2.7x10-8 – 5x10-9 M) [40,46]
PDGF RTK inhibitor Small molecule or natural product Primary target of this compound Hs Inhibition 7.9 pIC50 10
⤷ pIC50 7.9 (IC50 1.2x10-8 M) [10]
Description: Inhibition of PDGFR autophosphorylation in human G292 cells
ilorasertib Small molecule or natural product Click here for species-specific activity table Hs Inhibition 7.9 pIC50 13
⤷ pIC50 7.9 (IC50 1.3x10-8 M) [13]
Description: Measuring inhibition of kinase activity in a biochemical assay.
tafetinib Small molecule or natural product Click here for species-specific activity table Hs Inhibition 7.8 pIC50 47
⤷ pIC50 7.8 (IC50 1.4x10-8 M) [47]
Description: In a radiometric biochemical protein kinase assay.
MK-2461 Small molecule or natural product Click here for species-specific activity table Hs Inhibition 7.7 pIC50 36
⤷ pIC50 7.7 (IC50 2.2x10-8 M) [36]
KBP-7018 Small molecule or natural product Click here for species-specific activity table Immunopharmacology Ligand Hs Inhibition 7.6 pIC50 18
⤷ pIC50 7.6 (IC50 2.5x10-8 M) [18]
BPR1R024 Small molecule or natural product Click here for species-specific activity table Hs Inhibition 7.5 pIC50 24
⤷ pIC50 7.5 (IC50 3.15x10-8 M) [24]
orantinib Small molecule or natural product Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 7.3 pIC50 20
⤷ pIC50 7.3 (IC50 5x10-8 M) [20]
sorafenib Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 7.2 pIC50 52
⤷ pIC50 7.2 (IC50 5.7x10-8 M) [52]
sorafenib Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Mm Inhibition 7.2 pIC50 49
⤷ pIC50 7.2 (IC50 5.7x10-8 M) [49]
nintedanib Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 7.2 pIC50 16
⤷ pIC50 7.2 (IC50 6.5x10-8 M) [16]
linifanib Small molecule or natural product Click here for species-specific activity table Hs Inhibition 7.2 pIC50 1
⤷ pIC50 7.2 (IC50 6.6x10-8 M) [1]
PDGF receptor tyrosine kinase inhibitor III Small molecule or natural product Primary target of this compound Hs Inhibition 7.1 pIC50 29
⤷ pIC50 7.1 (IC50 8x10-8 M) [29]
pazopanib Small molecule or natural product Approved drug Click here for species-specific activity table Hs Inhibition 7.1 pIC50 14
⤷ pIC50 7.1 (IC50 8.4x10-8 M) [14]
AGL 2043 Small molecule or natural product Primary target of this compound Hs Inhibition 7.1 pIC50 12
⤷ pIC50 7.1 (IC50 9x10-8 M) [12]
Description: Using purified human PDGFRβ
ibcasertib Small molecule or natural product Click here for species-specific activity table Hs Inhibition 7.0 pIC50 54
⤷ pIC50 7.0 (IC50 9.3x10-8 M) [54]
Description: Inhibition in a biochemical assay.
CHMFL-KIT-64 Small molecule or natural product Click here for species-specific activity table Hs Inhibition 7.0 pIC50 51
⤷ pIC50 7.0 (IC50 9.7x10-8 M) [51]
Description: In a biochemical assay.
TAK-632 Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibition 6.9 pIC50 35
⤷ pIC50 6.9 (IC50 1.2x10-7 M) [35]
Description: Biochemical enzyme inhibition assay.
Flt-3 inhibitor II Small molecule or natural product Click here for species-specific activity table Hs Inhibition 6.8 pIC50 28
⤷ pIC50 6.8 (IC50 1.71x10-7 M) [28]
tandutinib Small molecule or natural product Click here for species-specific activity table Hs Inhibition 6.7 pIC50 21
⤷ pIC50 6.7 (IC50 2x10-7 M) [21]
Ki-20227 Small molecule or natural product Click here for species-specific activity table Hs Inhibition 6.7 pIC50 34
⤷ pIC50 6.7 (IC50 2.17x10-7 M) [34]
flumbatinib Small molecule or natural product Approved drug Click here for species-specific activity table Hs Inhibition 6.5 pIC50 27
⤷ pIC50 6.5 (IC50 3.07x10-7 M) [27]
SU5402 Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 6.3 pIC50 45
⤷ pIC50 6.3 (IC50 5.1x10-7 M) [45]
zoligratinib Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 6.3 pIC50 32
⤷ pIC50 6.3 (IC50 5.6x10-7 M) [32]
vatalanib Small molecule or natural product Click here for species-specific activity table Hs Inhibition 6.2 pIC50 4
⤷ pIC50 6.2 (IC50 6x10-7 M) [4]
semaxanib Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 6.2 pIC50 4
⤷ pIC50 6.2 (IC50 6.8x10-7 M) [4]
masitinib Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibition 6.1 pIC50 9
⤷ pIC50 6.1 (IC50 8x10-7 M) [9]
GTP-14564 Small molecule or natural product Click here for species-specific activity table Hs Inhibition 6.0 pIC50 31
⤷ pIC50 6.0 (IC50 1x10-6 M) [31]
sotuletinib Small molecule or natural product Click here for species-specific activity table Immunopharmacology Ligand Hs Inhibition 5.2 pIC50 43
⤷ pIC50 5.2 (IC50 5.86x10-6 M) [43]
seralutinib Small molecule or natural product Click here for species-specific activity table Hs Inhibition - - 55
⤷ [55]
View species-specific inhibitor tables
Inhibitor Comments
Note that sunitinib inhibits a range of additional kinases, including platelet-derived growth factor receptor α (PDGFRα), vascular endothelial growth factor receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3) and colony stimulating factor receptor Type 1 (CSF-1R).
The experiments measuring the ability of PDGF RTK inhibitor to inhibit PDGFR autophosphorylation were carried out in intact human cells, so it is impossible to specify the isozyme involved in the interaction. We nominally map the interaction to the beta isozyme for data retrieval purposes only.
DiscoveRx KINOMEscan® screen Click here for help
A screen of 72 inhibitors against 456 human kinases. Quantitative data were derived using DiscoveRx KINOMEscan® platform.
http://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan
Reference: 8,50
Key to terms and symbols Click column headers to sort
Target used in screen: PDGFRB
Ligand Sp. Type Action Value Parameter
sunitinib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 10.1 pKd
Ki-20227 Small molecule or natural product Hs Inhibitor Inhibition 9.5 pKd
SU-14813 Small molecule or natural product Hs Inhibitor Inhibition 9.5 pKd
cediranib Small molecule or natural product Hs Inhibitor Inhibition 9.5 pKd
axitinib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 9.2 pKd
dasatinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 9.2 pKd
foretinib Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 9.0 pKd
PD-173955 Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 8.9 pKd
staurosporine Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 8.7 pKd
linifanib Small molecule or natural product Hs Inhibitor Inhibition 8.7 pKd
Displaying the top 10 most potent ligands  View all ligands in screen »
EMD Millipore KinaseProfilerTM screen/Reaction Biology Kinase HotspotSM screen Click here for help
A screen profiling 158 kinase inhibitors (Calbiochem Protein Kinase Inhibitor Library I and II, catalogue numbers 539744 and 539745) for their inhibitory activity at 1µM and 10µM against 234 human recombinant kinases using the EMD Millipore KinaseProfilerTM service.

A screen profiling the inhibitory activity of 178 commercially available kinase inhibitors at 0.5µM against a panel of 300 recombinant protein kinases using the Reaction Biology Corporation Kinase HotspotSM platform.

http://www.millipore.com/techpublications/tech1/pf3036
http://www.reactionbiology.com/webapps/main/pages/kinase.aspx

Reference: 2,11
Key to terms and symbols Click column headers to sort
Target used in screen: PDGFRβ/PDGFRb
Ligand Sp. Type Action % Activity remaining at 0.5µM % Activity remaining at 1µM % Activity remaining at 10µM
staurosporine Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 2.3 3.0 1.0
dasatinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 2.5
SU11652 Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 9.3 1.0 1.0
PDK1/Akt/Flt dual pathway inhibitor Small molecule or natural product Hs Inhibitor Inhibition 11.4 120.0 111.0
sorafenib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 12.0
K-252a Small molecule or natural product Hs Inhibitor Inhibition 14.6 46.0 8.0
midostaurin Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 14.8 46.0 25.0
dovitinib Small molecule or natural product Hs Inhibitor Inhibition 17.2
masitinib Small molecule or natural product Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 17.3
sunitinib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 17.6
Displaying the top 10 most potent ligands  View all ligands in screen »
Immuno Process Associations
Immuno Process:  Immune system development
Clinically-Relevant Mutations and Pathophysiology Click here for help
Disease:  Basal ganglia calcification, idiopathic, 4; IBGC4
Synonyms: Basal ganglia calcification [Disease Ontology: DOID:0060230]
Bilateral striopallidodentate calcinosis [Orphanet: ORPHA1980]
Disease Ontology: DOID:0060230
OMIM: 615007
Orphanet: ORPHA1980
References:  33
Disease:  Chronic myelomonocytic leukemia
Orphanet: ORPHA98823
Disease:  Myeloid neoplasm associated with PDGFRB rearrangement
Orphanet: ORPHA168950
Disease:  Myeloproliferative disorder, chronic, with eosinophilia
Synonyms: Unclassified chronic myeloproliferative disease [Orphanet: ORPHA86830]
OMIM: 131440
Orphanet: ORPHA86830
Disease:  Myofibromatosis, infantile, 1; IMF1
Synonyms: Infantile myofibromatosis [Orphanet: ORPHA2591]
OMIM: 228550
Orphanet: ORPHA2591

References

Show »

1. Albert DH, Tapang P, Magoc TJ, Pease LJ, Reuter DR, Wei RQ, Li J, Guo J, Bousquet PF, Ghoreishi-Haack NS et al.. (2006) Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther, 5 (4): 995-1006. [PMID:16648571]

2. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. (2011) Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol, 29 (11): 1039-45. [PMID:22037377]

3. Blum A, Dorsch D, Linde N, Brandstetter S, Buchstaller HP, Busch M, Glaser N, Grädler U, Ruff A, Petersson C et al.. (2023) Identification of M4205─A Highly Selective Inhibitor of KIT Mutations for Treatment of Unresectable Metastatic or Recurrent Gastrointestinal Stromal Tumors. J Med Chem, 66 (4): 2386-2395. [PMID:36728508]

4. Bold G, Altmann KH, Frei J, Lang M, Manley PW, Traxler P, Wietfeld B, Brüggen J, Buchdunger E, Cozens R et al.. (2000) New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J Med Chem, 43 (12): 2310-23. [PMID:10882357]

5. Chao Q, Sprankle KG, Grotzfeld RM, Lai AG, Carter TA, Velasco AM, Gunawardane RN, Cramer MD, Gardner MF, James J et al.. (2009) Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor. J Med Chem, 52 (23): 7808-16. [PMID:19754199]

6. Cho TP, Dong SY, Jun F, Hong FJ, Liang YJ, Lu X, Hua PJ, Li LY, Lei Z, Bing H et al.. (2010) Novel potent orally active multitargeted receptor tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of 2-indolinone derivatives. J Med Chem, 53 (22): 8140-9. [PMID:21028894]

7. Czako B, Marszalek JR, Burke JP, Mandal P, Leonard PG, Cross JB, Mseeh F, Jiang Y, Chang EQ, Suzuki E et al.. (2020) Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R. J Med Chem, 63 (17): 9888-9911. [PMID:32787110]

8. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol, 29 (11): 1046-51. [PMID:22037378]

9. Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Castéran N, Borge L, Hajem B, Lermet A, Sippl W et al.. (2009) Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS ONE, 4 (9): e7258. [PMID:19789626]

10. Furuta T, Sakai T, Senga T, Osawa T, Kubo K, Shimizu T, Suzuki R, Yoshino T, Endo M, Miwa A. (2006) Identification of potent and selective inhibitors of PDGF receptor autophosphorylation. J Med Chem, 49 (7): 2186-92. [PMID:16570914]

11. Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R, Harvey KJ. (2013) A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. Biochem J, 451 (2): 313-28. [PMID:23398362]

12. Gazit A, Yee K, Uecker A, Böhmer FD, Sjöblom T, Ostman A, Waltenberger J, Golomb G, Banai S, Heinrich MC et al.. (2003) Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. Bioorg Med Chem, 11 (9): 2007-18. [PMID:12670652]

13. Glaser KB, Li J, Marcotte PA, Magoc TJ, Guo J, Reuter DR, Tapang P, Wei RQ, Pease LJ, Bui MH et al.. (2012) Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther, 343 (3): 617-27. [PMID:22935731]

14. Harris PA, Boloor A, Cheung M, Kumar R, Crosby RM, Davis-Ward RG, Epperly AH, Hinkle KW, Hunter 3rd RN, Johnson JH et al.. (2008) Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem, 51 (15): 4632-40. [PMID:18620382]

15. Heinrich MC, Griffith D, McKinley A, Patterson J, Presnell A, Ramachandran A, Debiec-Rychter M. (2012) Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res, 18 (16): 4375-84. [PMID:22745105]

16. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J et al.. (2008) BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res, 68 (12): 4774-82. [PMID:18559524]

17. Ho CY, Ludovici DW, Maharoof US, Mei J, Sechler JL, Tuman RW, Strobel ED, Andraka L, Yen HK, Leo G et al.. (2005) (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells. J Med Chem, 48 (26): 8163-73. [PMID:16366598]

18. Huang Z, Li H, Zhang Q, Lu F, Hong M, Zhang Z, Guo X, Zhu Y, Li S, Liu H. (2017) Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis. ACS Med Chem Lett, 8 (11): 1142-1147. [PMID:29152045]

19. Jarusiewicz JA, Jeon JY, Connelly MC, Chen Y, Yang L, Baker SD, Guy RK. (2017) Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia. ACS Omega, 2 (5): 1985-2009. [PMID:28580438]

20. Kammasud N, Boonyarat C, Sanphanya K, Utsintong M, Tsunoda S, Sakurai H, Saiki I, André I, Grierson DS, Vajragupta O. (2009) 5-Substituted pyrido[2,3-d]pyrimidine, an inhibitor against three receptor tyrosine kinases. Bioorg Med Chem Lett, 19 (3): 745-50. [PMID:19110422]

21. Kelly LM, Yu JC, Boulton CL, Apatira M, Li J, Sullivan CM, Williams I, Amaral SM, Curley DP, Duclos N et al.. (2002) CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell, 1 (5): 421-32. [PMID:12124172]

22. Kim MH, Tsuhako AL, Co EW, Aftab DT, Bentzien F, Chen J, Cheng W, Engst S, Goon L, Klein RR et al.. (2012) The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett, 22 (15): 4979-85. [PMID:22765894]

23. Kitagawa D, Yokota K, Gouda M, Narumi Y, Ohmoto H, Nishiwaki E, Akita K, Kirii Y. (2013) Activity-based kinase profiling of approved tyrosine kinase inhibitors. Genes Cells, 18 (2): 110-22. [PMID:23279183]

24. Lee KH, Yen WC, Lin WH, Wang PC, Lai YL, Su YC, Chang CY, Wu CS, Huang YC, Yang CM et al.. (2021) Discovery of BPR1R024, an Orally Active and Selective CSF1R Inhibitor that Exhibits Antitumor and Immunomodulatory Activity in a Murine Colon Tumor Model. J Med Chem, 64 (19): 14477-14497. [PMID:34606263]

25. Liu F, Li S, Chen P, Gu Y, Wang S, Wang L, Chen C, Wang R, Yuan Y. (2023) Salvianolic acid B inhibits hepatic stellate cell activation and liver fibrosis by targeting PDGFRβ. Int Immunopharmacol, 122: 110550. [PMID:37451016]

26. Liu G, Campbell BT, Holladay MW, Ford Pulido JM, Hua H, Gitnick D, Gardner MF, James J, Breider MA, Brigham D et al.. (2012) Discovery of AC710, a Globally Selective Inhibitor of Platelet-Derived Growth Factor Receptor-Family Kinases. ACS Med Chem Lett, 3 (12): 997-1002. [PMID:24900421]

27. Luo H, Quan H, Xie C, Xu Y, Fu L, Lou L. (2010) HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance. Leukemia, 24 (10): 1807-9. [PMID:20703259]

28. Mahboobi S, Uecker A, Sellmer A, Cénac C, Höcher H, Pongratz H, Eichhorn E, Hufsky H, Trümpler A, Sicker M et al.. (2006) Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem, 49 (11): 3101-15. [PMID:16722630]

29. Matsuno K, Ushiki J, Seishi T, Ichimura M, Giese NA, Yu JC, Takahashi S, Oda S, Nomoto Y. (2003) Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 3. Replacement of quinazoline moiety and improvement of metabolic polymorphism of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives. J Med Chem, 46 (23): 4910-25. [PMID:14584942]

30. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB et al.. (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res, 9 (1): 327-37. [PMID:12538485]

31. Murata K, Kumagai H, Kawashima T, Tamitsu K, Irie M, Nakajima H, Suzu S, Shibuya M, Kamihira S, Nosaka T et al.. (2003) Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3). J Biol Chem, 278 (35): 32892-8. [PMID:12815052]

32. Nakanishi Y, Akiyama N, Tsukaguchi T, Fujii T, Sakata K, Sase H, Isobe T, Morikami K, Shindoh H, Mio T et al.. (2014) The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. Mol Cancer Ther, 13 (11): 2547-58. [PMID:25169980]

33. Nicolas G, Pottier C, Charbonnier C, Guyant-Maréchal L, Le Ber I, Pariente J, Labauge P, Ayrignac X, Defebvre L, Maltête D et al.. (2013) Phenotypic spectrum of probable and genetically-confirmed idiopathic basal ganglia calcification. Brain, 136 (Pt 11): 3395-407. [PMID:24065723]

34. Ohno H, Kubo K, Murooka H, Kobayashi Y, Nishitoba T, Shibuya M, Yoneda T, Isoe T. (2006) A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther, 5 (11): 2634-43. [PMID:17121910]

35. Okaniwa M, Hirose M, Arita T, Yabuki M, Nakamura A, Takagi T, Kawamoto T, Uchiyama N, Sumita A, Tsutsumi S et al.. (2013) Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives. J Med Chem, 56 (16): 6478-94. [PMID:23906342]

36. Pan BS, Chan GK, Chenard M, Chi A, Davis LJ, Deshmukh SV, Gibbs JB, Gil S, Hang G, Hatch H et al.. (2010) MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res, 70 (4): 1524-33. [PMID:20145145]

37. Panek RL, Lu GH, Klutchko SR, Batley BL, Dahring TK, Hamby JM, Hallak H, Doherty AM, Keiser JA. (1997) In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. J Pharmacol Exp Ther, 283 (3): 1433-44. [PMID:9400019]

38. Patyna S, Laird AD, Mendel DB, O'farrell AM, Liang C, Guan H, Vojkovsky T, Vasile S, Wang X, Chen J et al.. (2006) SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther, 5 (7): 1774-82. [PMID:16891463]

39. Ramurthy S, Taft BR, Aversa RJ, Barsanti PA, Burger MT, Lou Y, Nishiguchi GA, Rico A, Setti L, Smith A et al.. (2020) Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic. J Med Chem, 63 (5): 2013-2027. [PMID:31059256]

40. Renhowe PA, Pecchi S, Shafer CM, Machajewski TD, Jazan EM, Taylor C, Antonios-McCrea W, McBride CM, Frazier K, Wiesmann M et al.. (2009) Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors. J Med Chem, 52 (2): 278-92. [PMID:19113866]

41. Roberts WG, Whalen PM, Soderstrom E, Moraski G, Lyssikatos JP, Wang HF, Cooper B, Baker DA, Savage D, Dalvie D et al.. (2005) Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. Cancer Res, 65 (3): 957-66. [PMID:15705896]

42. Shim AH, Liu H, Focia PJ, Chen X, Lin PC, He X. (2010) Structures of a platelet-derived growth factor/propeptide complex and a platelet-derived growth factor/receptor complex. Proc Natl Acad Sci USA, 107 (25): 11307-12. [PMID:20534510]

43. Strachan DC, Ruffell B, Oei Y, Bissell MJ, Coussens LM, Pryer N, Daniel D. (2013) CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8(+) T cells. Oncoimmunology, 2 (12): e26968. [PMID:24498562]

44. Sun L, Liang C, Shirazian S, Zhou Y, Miller T, Cui J, Fukuda JY, Chu JY, Nematalla A, Wang X et al.. (2003) Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem, 46 (7): 1116-9. [PMID:12646019]

45. Sun L, Tran N, Liang C, Tang F, Rice A, Schreck R, Waltz K, Shawver LK, McMahon G, Tang C. (1999) Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. J Med Chem, 42 (25): 5120-30. [PMID:10602697]

46. Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C, Reece D, Heise C, Stewart AK. (2005) CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood, 105 (7): 2941-8. [PMID:15598814]

47. Wang D, Tang F, Wang S, Jiang Z, Zhang L. (2012) Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor. Cancer Chemother Pharmacol, 69 (1): 173-83. [PMID:21638122]

48. Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO et al.. (2005) AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res, 65 (10): 4389-400. [PMID:15899831]

49. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M et al.. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 64 (19): 7099-109. [PMID:15466206]

50. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem Biol, 17 (11): 1241-9. [PMID:21095574]

51. Wu Y, Wang B, Wang J, Qi S, Zou F, Qi Z, Liu F, Liu Q, Chen C, Hu C et al.. (2019) Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors. J Med Chem, 62 (13): 6083-6101. [PMID:31250638]

52. You WK, Sennino B, Williamson CW, Falcón B, Hashizume H, Yao LC, Aftab DT, McDonald DM. (2011) VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res, 71 (14): 4758-68. [PMID:21613405]

53. Zhou Y, Chen Y, Tong L, Xie H, Wen W, Zhang J, Xi Y, Shen Y, Geng M, Wang Y et al.. (2012) AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR. J Cell Mol Med, 16 (10): 2321-30. [PMID:22304225]

54. Zhou Y, Shan S, Li ZB, Xin LJ, Pan DS, Yang QJ, Liu YP, Yue XP, Liu XR, Gao JZ et al.. (2017) CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency. Cancer Sci, 108 (3): 469-477. [PMID:28004478]

55. Zisman LS. (2014) Non-selective kinase inhibitors. Patent number: WO2014110200A1. Assignee: Zisman LS. Priority date: 10/01/2013. Publication date: 17/07/2014.

How to cite this page

Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family: platelet derived growth factor receptor beta. Last modified on 22/08/2024. Accessed on 02/12/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=1804.